Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Swedish MTP Council launched a national evaluation of spinal cord stimulation devices within the Orderly introduction framework

Swedish Medical Technologies Product (MTP) Council is currently evaluating devices for spinal cord stimulation (SCS) as part of the Orderly introduction framework.

The Orderly introduction framework aimed to manage the national introduction of novel technologies is working as permanent from the beginning of 2020. This is a staged process, including horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation by the Dental and Pharmaceutical Benefits Agency (TLV), and recommendations by the MTP Council to regions about the introduction of the method.

On September 23, 2022, MTP Council commissioned the TLV to perform a health economic evaluation of five devices for SCS. Based on the TLV assessment, MTP Council will develop recommendations to regions regarding the introduction of SCS devices and the criteria for use.

See more information in Swedish here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).